Advances in small-molecule drug discovery for triple-negative breast cancer

Fosu-Mensah, Nelly ORCID: https://orcid.org/0000-0003-1872-8529, Peris, María Sánchez, Weeks, Hoi Ping, Cai, Jun and Westwell, Andrew David ORCID: https://orcid.org/0000-0002-5166-9236 2015. Advances in small-molecule drug discovery for triple-negative breast cancer. Future Medicinal Chemistry 7 (15) , pp. 2019-2039. 10.4155/fmc.15.129

Preview

PDF - Accepted Post-Print Version Download (1MB) | Preview

Abstract

Triple-negative breast cancer (TNBC) is a subtype of poor prognosis, highly invasive and difficult-to-treat breast cancers accounting for approximately 15% of clinical cases. Given the poor outlook and lack of sustained response to conventional therapies, TNBC has been the subject of intense studies on new therapeutic approaches in recent years. The development of targeted cancer therapies, often in combination with established chemotherapy, has been applied to a number of new clinical studies in this setting in recent years. This review will highlight recent therapeutic advances in TNBC, focusing on small-molecule drugs and their associated biological mechanisms of action, and offering the possibility of improved prospects for this patient group in the near future.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Publisher:	Future Science Ltd
ISSN:	1756-8919
Date of First Compliant Deposit:	30 March 2016
Date of Acceptance:	4 August 2015
Last Modified:	08 Nov 2023 00:37
URI:	https://orca.cardiff.ac.uk/id/eprint/81012

Citation Data

Cited 12 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item